Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs.
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 6, 2022
Entact Bio
|
Series A | $81M | Biopharma | — |
Apr 19, 2021
Adaptate Biotherapeutics
|
Series A | £13M | Biotechnology | — |
Mar 19, 2021
X4 Pharmaceuticals
|
Post-IPO Equity | $55M | Biotechnology | — |
Jan 7, 2021
Scorpion Therapeutics
|
Series B | $162M | Biotechnology | — |
Oct 26, 2020
Scorpion Therapeutics
|
Series A | $108M | Biotechnology | — |